DNA Methylation Profiles of the Brain-Derived Neurotrophic Factor (BDNF) Gene as a Potent Diagnostic Biomarker in Major Depression by Fuchikami, Manabu et al.
DNA Methylation Profiles of the Brain-Derived
Neurotrophic Factor (BDNF) Gene as a Potent Diagnostic
Biomarker in Major Depression
Manabu Fuchikami
1, Shigeru Morinobu
1*, Masahiro Segawa
1, Yasumasa Okamoto
1, Shigeto Yamawaki
1,
Norio Ozaki
2, Takeshi Inoue
3, Ichiro Kusumi
3, Tsukasa Koyama
3, Kounosuke Tsuchiyama
4, Takeshi
Terao
4
1Division of Frontier Medicine, Department of Psychiatry and Neurosciences, Graduate School of Medical Sciences, Hiroshima University, Hiroshima, Japan, 2Department
of Psychiatry and Molecular Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Department of Psychiatry, Hokkaido University Graduate School
of Medicine, Sapporo, Japan, 4Department of Neuropsychiatry, Oita University Faculty of Medicine, Yufu City, Oita, Japan
Abstract
Major depression, because of its recurring and life-threatening nature, is one of the top 10 diseases for global disease
burden. Major depression is still diagnosed on the basis of clinical symptoms in patients. The search for specific biological
markers is of great importance to advance the method of diagnosis for depression. We examined the methylation profile of
2 CpG islands (I and IV) at the promoters of the brain-derived neurotrophic factor (BDNF) gene, which is well known to be
involved in the pathophysiology of depression. We analyzed genomic DNA from peripheral blood of 20 Japanese patients
with major depression and 18 healthy controls to identify an appropriate epigenetic biomarker to aid in the establishment
of an objective system for the diagnosis of depression. Methylation rates at each CpG unit was measured using a
MassArrayH system (SEQUENOM), and 2-dimensional hierarchical clustering analyses were undertaken to determine the
validity of these methylation profiles as a diagnostic biomarker. Analyses of the dendrogram from methylation profiles of
CpG I, but not IV, demonstrated that classification of healthy controls and patients at the first branch completely matched
the clinical diagnosis. Despite the small number of subjects, our results indicate that classification based on the DNA
methylation profiles of CpG I of the BDNF gene may be a valuable diagnostic biomarker for major depression.
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Introduction
Major depression was among the 10 diseases with the greatest
global burden in 2001 [1] and it is predicted to become the second
leading causes of disability-adjusted life years in 2020 based on
systematic analyses of population health data [2]. There are marked
cross-national and cross-regional differences in the prevalence of
major depression [3,4,5,6,7]. In addition, diagnostic differences are
suggested to be associated with the varied proportion of patients
receiving any specific mental health care [3]. Although the
underlying reasons are not fully known, the difference in rates of
major depression across countries could conceivably be due in part
to social, economic, and cultural differences. On the other hand, the
diagnostic system for major depression, which rely on assessment of
patient symptoms, such as the Diagnostic and Statistical Manual of
Mental Disorders fourthedition (DSM-IV), rather than an objective
laboratory test, may also account for the difference in rates of major
depression. Hence, the search for biological markers for major
depression could be important for improving patient care and for
the development of more effective drug treatments.
Although numerous studies have been undertaken to identify
biomarkers in major depression, no biological markers proposed to
date, including the dexamethasone suppression test (DST) [8,9]
and the combined dexamethasone/corticotrophin-releasing hor-
mone (DEX/CRH) test [10], have been sufficiently specific to
warrant inclusion as a diagnostic criterion [11]. Likewise, Brunoni
et al. conducted a systematic review and meta-analysis of brain-
derived neurotrophic factor (BDNF) levels in patients with major
depression, which demonstrated a difference in blood BDNF levels
between pre-treatment patients and healthy controls. In fact, since
a number of studies showed decreased blood BDNF levels in
patients with major depression [12,13], it is possible that blood
BDNF levels could serve as a potential biomarker for major
depression. However, there is an evident overlap in the BDNF
levels between these patients with depression and healthy controls.
In this context, it would be of great interest to develop a highly
sensitive diagnostic biomarker for major depression [14].
One of the most important requirements for a clinically useful
biomarker is that it should be non-invasive. Towards that end,
analyses of protein, RNA, and DNA levels from blood samples
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or protein detection techniques can potentially be useful, the
instability of these molecules leads to lack of reproducibility of test
results and the need for normalization [15]. DNA-based analyses
are more convenient due to the amplifiable and stable nature of
DNA. Methylation of cytosine residues is in most cases chemically
and biologically stable over time, and epigenetic changes are
potentially reversible by treatment with pharmacological agents or
by environmental stimuli, whereas genetic changes are irreversible
[16]. Thus, great attention has been focused on the correlation
between the hypermethylation of promoter-associated CpG
islands and the transcriptional activity of genes, and the use of
DNA methylation patterns as a biomarker in cancer and other
complex or multifactorial diseases has been advocated [17,18,19].
Despite the promise of using DNA methylation as a biomarker,
few studies to date have examined the possibility of using epigenetic
biomarkers in psychiatric disorders [20]. Tsankova et al. recently
demonstrated that social defeat stress, an animal models of
depression, affects transcription of BDNF through changes in
histone acetylation and DNA methylation in the rat hippocampus
[21]. Itis well knownthat the stress-induced decreasesinBDNF and
antidepressant-stimulated increases in BDNF play important roles
in the pathophysiology and therapeutic mechanisms of depression,
respectively. In addition, a differenttypeof stimulus, depolarization,
was also reported to upregulate BDNF via a decrease in CpG
methyaltion at the promoter regions of the BDNF gene [22,23].
Based on these findings, we examined the methylation profile of
2 CpG islands at the promoters of exon I and IV of the BDNF
gene using genomic DNA from peripheral blood of Japanese
patients with major depression and healthy controls to identify an
appropriate epigenetic biomarker for the objective diagnosis of
depression.
Materials and Methods
Subjects
Twenty patients with major depression and 18 healthy controls
participated in this study. Demographic characteristics of the
participants are shown in Table 1. All subjects were Japanese. All
patients were diagnosed by trained psychiatrists according to DSM-
IV criteria (American Psychiatric Association, 1994), on the basis of
unstructured interviews and information from medical records, and
through the use of a structured clinical interview, the Japanese
version of the Mini-International Neuropsychiatric Interview
[24,25] by a research psychiatrist. The severity of depression was
evaluated using the Hamilton Rating Scale for Depression (HAM-
D). All patients were free of any current or past diagnoses of
substance-related disorders. Healthy controls, free of any current or
past psychiatric or physical diagnoses and any first-degree relatives
with major depression, were recruited by advertisement. Blood
samples were collected at Hiroshima University hospital, Nagoya
University hospital, Hokkaido University hospital, and Oita
University hospital. This study was approved by the Ethics
Committee of the Hiroshima University School of Medicine, by
the ethics committee of the Nagoya University School of Medicine,
by the ethics committee of the Hokkaido University School of
Medicine, and by the Oita University Faculty of Medicine ethics
committee. All subjects received a description of this study and gave
written informed consent.
Selection of genomic regions of the BDNF gene for
methylation analysis
With respect to proximal promoter activity and preinitiation,
the first exon of a gene is generally considered to be important in
transcription [26,27]. Alternatively, methylation of CpGs upstream
of exon IV is proposed to be involved in the regulation of the BDNF
gene under physical and pathological conditions [22,28]. Thus, we
chose the CpG island of the BDNF gene upstream of exon I (CpG I)
and the cluster of CpGs at the upstream of exon IV (CpG IV) as
targets for methylation analysis. The sequence of CpG I was
identified by the useof theUCSC genomebrowser (http://genome.
ucsc.edu/), (chr11:27743473–27744564 %GC=60.5 and Obs/
Exp CpG=0.83). Since no CpG island was found based on the
CpG island criteria of the UCSC genome browser (%GC.50,
length .200 bp, Obs/Exp CpG.0.6) upstream of exon IV, we
selected the area which was found to have proximal promoter
activity (chr11:27722840–27723980) in previous experiments
[23,28]. Methylation primers were designed using Epidesigner
software (http://www.epidesigner.com/) with the software’s CpG
island criteria (%GC.50, Obs/Exp CpG.0.6). The schemas of
target regions of the BDNF gene used for methylation analysis and
the primers used for PCR amplification are shown in Figure 1.
DNA methylation analysis by MassARRAY
All blood samples were collected between 11:00 AM to 1:00
PM, prior to lunch. Blood samples (5 ml) were collected and
placed in a vacuum tube containing heparin sodium and stored at
280uC. Genomic DNA was isolated using DNeasyH Blood &
Tissue Kits (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. Genomic DNA (1 mg) was converted with
sodium bisulfite using the EZ DNA methylation kit (Zymo Re-
search, Orange, CA). The concentration of sodium bisulfite-
treated DNA was measured using an ND-1000 spectrophotometer
(NanoDrop Technologies, Inc., Wilmington, DE, USA), and
10 ng of treated DNA was applied in a region-specific PCR. The
PCR reactions were carried out in a total volume of 5 mL using
1 mmol of each primer, 200 mM dNTP, 0.2 U HotStar Taq DNA
polymerase (Qiagen), 15 mM MgCl2, and 106PCR buffer (final
concentration 16). One of the two primers in the PCR amplifi-
cation of the target regions is tagged with a T7 promoter sequence:
cagtaatacgactcactatagggagaaggct. This includes ggg transcription
start and an 8-bp insert (agaaggct) on the 59 end. The reaction mix
was preactivated for 4 min at 95uC. The reactions were amplified
in 45 cycles of 95uC for 20 s, 56uC for 30 s, and 72uC for 60 s
followed by 72uC for 3 min. Unincorporated dNTPs were
Table 1. Demographic characteristics of subjects.
Group
Age (years:
Mean ±S.D.)
HAM-D score
(Mean ±S.D.)
Duration of untreated
(Weeks: Mean ±S.D.)
Education (years:
Mean ±S.D.)
Control (N=18, 10M/8F) 42.369.6 13.7862.05
Major depression (N=20, 8M/12F, not medicated) 45.6612.5 21.462.76 9.8569.84 13.961.61
HAM-D: Hamilton Rating Scale for Depression.
doi:10.1371/journal.pone.0023881.t001
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Shrimp Alkaline Phosphatase (SAP) (Sequenom, Inc., San Diego,
CA, USA). The reaction was incubated at 37uC for 20 min and
SAP was then heat inactivated for 5 min at 85uC. Sub-
sequently, 2 mL of the PCR reaction were incubated for 3 h at
37uC with 5 ml of Transcleave mix (3.15 ml RNAse-free water,
0.89 ml5 6T7 Polymerase Buffer, 0.24 ml T Cleavage Mix, 0.22 ml
100 mM DTT, 0.44 ml T7 RNA&DNA Polymerase, 0.06 ml
RNAse A (Sequenom) for concurrent in vitro transcription and
base-specific cleavage. The resultant 10 to 20 nl cleavage reaction
samples were spotted onto silicon matrix-preloaded chips (Spectro-
CHIP; SEQUENOM) using a MassARRAY nanodispenser
(SEQUENOM), and analyzed using the MassARRAY Compact
System matrix-assisted laser desorption/ionization-time-of-flight
mass spectrometer (MALDI-TOF) (SEQUENOM). The spectra’s
methylation ratios were calculated using EpiTYPER software v1.0
(SEQUENOM). Triplicate independent analyses from sodium
bisulfite-treated DNA sample were undertaken. The method yields
quantitative results for each of the sequence-defined analytic units
referred to as CpG units, which contain either 1 individual CpG
site or an aggregate of downstream CpG sites. These methods
divided 81 CpG sites in CpG I into 53 CpG units, and 28 CpG
sites in CpG IV into 24 CpG units.
Statistical analysis
Poor-quality and non-valuable data for the quantitative
methylation of each CpG unit measured by MALDI-TOF-MS
were excluded. CpG units that yielded data in greater than 25% of
the samples passed initial quality control (QC). From these data,
samples that yielded data for greater than 80% for all CpG units
within an amplicon were met standard for inclusion in further
analysis for that sample/amplicon pair. In subsequent analyses,
CpG units for which data were available for less than 50% of all
samples were excluded; samples which had data available for less
than 50% of all CpG units were also excluded. These QC steps
resulted in 35 available CpG units out of 53 CpG units in CpG I,
and 19 available CpG units out of 24 CpG units in CpG IV.
The measurements after QC were combined in a data matrix,
which was used in a 2-dimensional hierarchical clustering analysis
with the ‘R’ software package for statistical computing (available at
CRAN, http://cran.r=project.org/). Hierarchical clustering
analyses were performed using hclust in the R cluster package,
with Euclidean metric and complete linkage. Samples with closer
methylation patterns are closely clustered.
We performed Peason’s correlation coefficient test to examine
the correlation between the methylation rate of each CpG units
and the age of both patients and healthy controls or the total
HAM-D scores in patients. The difference in the methylation rates
of each CpG units between healthy controls and patients was
analyzed by independent t-test. Significance was set at P,0.05.
Results
The Raw Data from MassArray analysis indicating the
methylation rates of each CpG units are shown as Data S1 and
Data S2. Methylation rates of any CpG units had no statistically
significant correlations with age or total HAM-D scores (Data S3).
DNA methylation patterns of CpG I
Two-way hierarchical clustering analysis of methylation rates of
CpG units at CpG I was undertaken to classify samples and CpG
units into clusters according to their similarity, and dendrograms
were used to visualize the results. The DNA methylation profiles at
BDNF CpG I of all subjects are shown in heat map format
(Figure 2). The dendrogram acquired from clustering analysis is
shown at left side of Figure 2. At the first branch of the dendrogram,
we could distinguish between healthy controls and patients with
major depression in complete concordance with classification based
Figure 1. The schema of CpGs and primers used for DNA methylation analyses. The target region used for methylation analysis consists of
1092 bp including 81 CpGs upstream of exon I, and 1137 bp including 28 CpGs upstream of exon IV.
doi:10.1371/journal.pone.0023881.g001
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similarity of subjects; the greater the height, the more similarity
among divided subjects. Next, we analyzed the difference in
methyration rates of each CpG units between healthy controls and
patients with major depression (Table 2). The methylation rates of
29 CpG units out of 35 CpG units in BDNF CpG I were
significantly different between these two groups.
DNA methylation patterns of CpG IV
Similar to the analysis of CpG I, we applied 2-way hierarchical
clustering analysis of methylation rates of CpG units at CpG IV.
The DNA methylation profiles at BDNF CpG IV of all subjects
are shown in heat map format (Figure 3). The dendrogram
acquired from clustering analysis is shown at left side of Figure 3.
We were unable to distinguish subjects at any height in the
dendrogram.
Discussion
In the present study, we were able to accurately distinguish
between patients with major depression and healthy controls,
based on the methylation profiles of CpG units within CpG I, but
not CpG IV, of the BDNF gene, and these results were com-
pletely concordant with clinical diagnoses. This finding indicates
that quantitative methylation analysis within CpG I of the
BDNF gene is helpful in the diagnosis of patients with major
depression.
To our knowledge, this is the first study postulating the
possibility of a DNA methylation marker in psychiatric disorders,
though increased methylation of the promoter/exon IV of the
BDNF gene was previously reported in Wernicke’s area of the
brain in suicide subjects [29]. Whereas Keller et al. demonstrated
that a higher degree of methylation corresponded to lower BDNF
mRNA in Wernicke’s area, the influence of changes in DNA
methylation profiles within CpG I on the transcription of the
BDNF gene in blood are unknown. However, it is not necessary
that DNA methylation markers for diseases always induces gene
silencing [19].
Some limitations of the current study warrant mention. First,
the sample size (n=18 for control, n=20 for major depression) in
the current study is relatively small. Further studies using large
samples are necessary for the clinical application in the future.
Figure 2. Hierarchic cluster analysis of subjects and their methylation profiles at CpG I of the BDNF gene. Two-way hierarchic cluster
analysis of 38 samples (rows) and DNA methylation of CpG units at CpG I of the BDNF gene (columns). DNA methylation values are depicted by a
pseudocolor scale as indicated (methylation increases from red [nonmethylated] to white [methylated]). Samples with overall poor data quality were
removed before clustering. Gray denotes data of poor quality. Samples are color-coded according to the diagnoses of samples (legend depicted
lower left). The stars(w) ahead of several CpG units indicate CpG units which have statistically significant p-values in subsequent analyses by t-test.
doi:10.1371/journal.pone.0023881.g002
DNA Methylation as a Biomarker in Major Depression
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23881Second, although numerous studies have demonstrated that the
levels of gene expression in blood change after pharmacotherapy
of psychiatric disorders [30,31], it is uncertain whether the
methylation profiles of DNA from peripheral blood in humans are
affected by antidepressants. In this context, further studies
examining the methylation profiles of CpG I in response to
antidepressant treatment could reveal the influence of antidepres-
sants on the DNA methylation, and subsequently identify whether
the methylation profiles of CpG I from patients with major
depression found in the current study are state or trait markers in
major depression. Third, in contrast to SNPs and haplotypes [32],
it is uncertain whether or not there are ethnic differences in DNA
methylation profiles or not. Thus, these results may not apply to
other races because of ethnic differences. Lastly, we evaluated the
methylation profiles within only 2 CpG sites of the BDNF gene,
but not genome-wide DNA methylation.
Based on MassARRAY analyses of the methylation profiles
within the CpG island at the promoter of exon I of the BDNF gene
in peripheral blood, we were able to accurately classify subjects
into 2 groups (major depression, and healthy controls), and this
classification was in good agreement with that obtained by clinical
diagnosis. Thus, we propose that the DNA methylation profiles at
CpG I of the BDNF gene could be a valid biomarker for the
diagnosis of major depression.
Table 2. Results of independent t-test between healthy controls and patients of major depression.
Control (mean±S.E.M) Depression (mean±S.E.M) t-value P-value
CpG_1 12.460.47 2.160.27 19.6 8.5610
221
CpG_2 7.2960.34 5.060.42 4.14 1.98610
24
CpG_3 8.2660.58 3.2560.47 6.75 7.04610
28
CpG_4 58.8564.12 2.461.19 13.76 6.58610
216
CpG_5 4.6960.53 0.6560.28 6.88 4.67610
28
CpG_6 8.2660.58 3.2560.47 6.75 7.04610
28
CpG_7 12.4460.47 2.160.27 19.6 8.5610
221
CpG_8,9 12.8860.28 10.960.69 2.56 0.015
CpG_14 5.2260.93 4.2560.77 0.81 0.422
CpG_15 14.2560.94 5.8560.54 7.96 1.89610
29
CpG_17 0.2260.13 0.960.37 21.66 0.106
CpG_18 7.9360.43 0.5560.22 15.63 1.26610
217
CpG_19,20,21 2.5560.48 10.6561.44 25.12 1.04610
25
CpG_22 3.8960.66 15.6962.57 24.23 1.52610
24
CpG_23 28.2965.02 3.1560.4 5.59 2.96610
26
CpG_24 14.3960.57 1.760.39 18.64 4.45610
220
CpG_28 3.7460.3 5.0560.34 22.85 7.12610
23
CpG_32 36.7762.23 62.361.4 29.89 8.34610
212
CpG_36 0.4560.21 9.461 28.34 6.24610
210
CpG_37 11.560.37 5.560.35 11.76 6.85610
214
CpG_47 6.0860.4 3.2560.22 6.45 1.75610
27
CpG_48 27.6860.88 1.5560.29 29.61 7.14610
227
CpG_50,51 6.360.26 5.560.42 1.57 0.126
CpG_52 4.2660.26 1.560.22 8.06 1.43610
29
CpG_59 2.460.29 260.26 1.04 0.305
CpG_61 8.8160.41 3.0560.34 10.99 4.73610
213
CpG_63 3.6960.43 2.1560.23 3.23 2.6610
23
CpG_71 74.2764.18 3.4560.43 17.77 2.12610
219
CpG_72,73 3.4360.33 3.6560.36 20.46 0.65
CpG_74,75 6.9460.35 5.9560.64 1.31 0.199
CpG_76 3.5760.59 5.460.66 22.04 0.049
CpG_77 3.6960.43 2.1560.23 3.23 2.7610
23
CpG_78 7.5360.75 2.5860.34 6.22 3.54610
27
CpG_79 060 0.00460.17 22.25 0.031
CpG_80,81 6.4360.39 8.2560.53 22.74 9.6610
23
The mean methylation rates among groups, t-value, P-value are shown. Significance was set at P,0.05.
doi:10.1371/journal.pone.0023881.t002
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